Grünenthal gains Zomig rights from AstraZeneca

7 June 2017 - Deborah Wilkes

Archived

Germany's Grünenthal is acquiring the global rights to AstraZeneca's migraine treatment Zomig (zolmitriptan) in a deal worth up to USD302 million. The deal excludes the rights in Japan.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: